Y-39983, a Selective Rho-Kinase Inhibitor, Attenuates Experimental Autoimmune Encephalomyelitis via Inhibition of Demyelination (2024)

FAQs

What is rho kinase inhibitor drugs for? ›

The use of ROCK inhibitors (RKIs) has been shown to improve corneal wound healing and endothelial regeneration. Because of this, RKIs are a promising therapeutic agent for corneal disease, but have also found applications in glaucoma and vitreoretinal disease.

Rho-associated kinase (Rho-kinase/ROCK/ROK) is an effector of the small GTPase Rho and belongs to the AGC family of kinases. Rho-kinase has pleiotropic functions including the regulation of cellular contraction, motility, morphology, polarity, cell division, and gene expression.

The mechanism of ROCK inhibitors' ability to decrease IOP is through direct action on the trabecular meshwork and Schlemm's canal cells (increases permeability), which play a large role in the resistance of aqueous humor outflow.

Rho-kinase inhibitors (rho-associated protein kinase inhibitor or ROCK inhibitor) are a series of compounds that target rho kinase (ROCK) and inhibit the ROCK pathway. Clinical trials have found that inhibition of the ROCK pathway contributes to the cardiovascular benefits of statin therapy.

The protein kinase inhibitors all have some degree of hepatotoxicity and many have been linked to cases of clinically apparent liver injury which can be severe and even fatal.

The main side effect of ROCK inhibitors is conjunctival hyperemia that is often present in more than half of the patients in certain formulations. Additional clinical trials investigating the reviewed treatment options of Rho kinase inhibitors are necessary to further validate previous findings on the topic.

Rho kinase (ROCK) is a serine/threonine kinase that undergoes activation by interaction with Rho GTPases. The Rho/ROCK signaling pathways control a wide range of fundamental cell functions, including cell adhesion, motility, proliferation, differentiation, and apoptosis.

Rho kinase (ROCK) inhibitors are a new class of glaucoma drugs with a novel mechanism of action and good safety profile. They exert neuroprotective effects, act on the trabecular tissue, increase the outflow of aqueous humor, and reduce intraocular pressure.

(KY-nays) A type of enzyme (a protein that speeds up chemical reactions in the body) that adds chemicals called phosphates to other molecules, such as sugars or proteins. This may cause other molecules in the cell to become either active or inactive.

Studies show that you can lower your intraocular pressure, or IOP, by doing exercises that raise your pulse by only twenty percent. You can do that easily with a twenty-minute walk, four times a week. If the weather outside is frightful, simple indoor calisthenics or yoga can do the trick, too!

How can I lower my IOP fast? ›

you should know that brimonidine eye drops may make you drowsy. Your vision may be blurry for a few minutes after you instill the eye drops. Do not drive a car or operate machinery until you know how this medication affects you. ask your doctor about the safe use of alcohol while you are using brimonidine eye drops.

Local adverse effects, however, including conjunctival hyperemia, subconjunctival hemorrhages and cornea verticillata, are common. Development of Rho kinase inhibitors targeted to the cells of the outflow pathway and the retina may allow these agents to have even greater clinical impact.

Netarsudil ophthalmic solution (0.02%) is an FDA-approved medication used to treat glaucoma and ocular hypertension. Introduced in December 2017, this therapeutic solution belongs to the class of rho-kinase inhibitors, demonstrating its efficacy in managing these eye conditions.

The RhoA/Rho-kinase pathway is now widely known to play important roles in many cellular functions, including contraction, motility, proliferation, and apoptosis, and its excessive activity induces oxidative stress and promotes the development of cardiovascular diseases.

These JAK inhibitors (Xeljanz, Cibinqo, Olumiant, Rinvoq and Jyseleca) are used to treat one or more of the following chronic inflammatory disorders: rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, axial spondyloarthritis, ulcerative colitis, atopic dermatitis and alopecia areata.

Certain kinases are more active in some types of cancer cells and blocking them may help keep the cancer cells from growing. Kinase inhibitors may also block the growth of new blood vessels that tumors need to grow. Some kinase inhibitors are used to treat cancer.

EGFR is found on the surface of some normal cells and is involved in cell growth. It may also be found at high levels on some types of cancer cells, which causes these cells to grow and divide. Blocking EGFR may keep cancer cells from growing. Some EGFR inhibitors are used to treat cancer.

An mTOR inhibitor immunosuppressant used to prevent organ transplant rejections, treat lymphangioleiomyomatosis, and treat adults with perivascular epithelioid cell tumors.